Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Universitatsklinikum Heidelberg |
| Country | Germany |
| Start Date | Jan 01, 2024 |
| End Date | Dec 31, 2026 |
| Duration | 1,095 days |
| Number of Grantees | 5 |
| Roles | Associated Partner; Participant; Coordinator |
| Data Source | European Commission |
| Grant ID | 101094804 |
Respiratory infections resulted in >7 million deaths in 2020 and were responsible for 7 of the last 9 pandemics, causing trillions of €s in economic losses.
Despite the importance of early detection for individual health and pandemic control, flawed sampling methods for respiratory infections limit the impact of highly-sensitive molecular diagnostics.
BreathForDx’s overall goal is to tackle this problem by establishing exhaled breath aerosol (XBA) as a novel, evidence-based sample for respiratory infections in three use cases: diagnosis, screening, and antimicrobial resistance, using tuberculosis (TB) as a model infection.
The project will leverage innovation in bioaerosol and material science, as well as the multidisciplinary (including academia, industry and NGOs) consortium’s track record of delivering transformative diagnostic innovation.
More specifically, we will optimise an innovative, easy-to-use, scalable XBA sampling device, and compare it to a face mask sampling device coupled with rapid molecular detection in three clinical studies.
We will evaluate the XBA sampling efficiency of these devices using the Respiratory Aerosol Sampling Chamber as a benchmark.
Next, we will assess performance of the devices for diagnosis of TB and drug-resistance among symptomatic patients in a high burden EU country.
In parallel, we will assess the feasibility of multiplexing XBA samples for multiple respiratory pathogens (i.e., TB, influenza, SARS-CoV-2) in a screening use case.
Accuracy and feasibility data will be complemented by data on acceptability and usability, as well as cost-effectiveness and impact modelling to inform the implementation potential of the novel devices across different use cases.
We envision a world in which a single breath sample, coupled with point-of-care molecular diagnostics, enables accessible and accurate pathogen and resistance detection of highly transmissible respiratory infections, thereby improving both individual and public health.
Avelo Ag; Institutul de Pneumoftiziologie Marius Nasta; Ospedale San Raffaele Srl; Universitatsklinikum Heidelberg; Desmond Tutu Health Foundation Npc
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant